AI is disrupting drug discovery faster than expected

If you aren’t paying attention to the companies behind a new wave of AI-driven drug development, you may end up missing out on essential investment opportunities. One company that has caught our attention is Chai Discovery, founded in 2024 by co-founder Joshua Meier. After graduating from Harvard, Meier began working as a researcher at OpenAI (OPAI.PVT) during the development of GPT-1 and GPT-2. He then worked at Meta's generative biology group, where he co-led the development of ESM1, the first transformer protein-language model. Chai Discovery is currently one of the buzziest startups in AI drug development. In December, the company completed a Series B funding round, raising an additional $130 million at a valuation of $1.3 billion, cementing its unicorn status. Backers include Silicon Valley heavyweights such as General Catalyst and OpenAI. The company also recently inked a deal with Eli Lilly (LLY), under which the drug giant will use Chai’s models. Yahoo Finance Executive Editor Brian Sozzi sits down with Meier on Opening Bid Unfiltered to go inside the world of AI-driven medicine. Yahoo Finance's Opening Bid Unfiltered brings you a high-octane take on the freshest analyst calls, wildest stock moves, and shrewdest commentary in the business world. Executive Editor Brian Sozzi puts Wall Street's finest through their paces in this essential conversation for every investor, before the stock market opens. Find this episode's transcripts and more episodes of Opening Bid Unfiltered at http://finance.yahoo.com/videos/series/opening-bid/. Thoughts? Questions? Fan mail? Please email us at [e-mail]. Yahoo Finance's Opening Bid Unfiltered is hosted by Brian Sozzi and produced by Langston Sessoms. Learn more about your ad choices. Visit megaphone.fm/adchoices